RIFATER®(rifampin, isoniazid and pyrazinamide USP)
WARNING
Severe and sometimes fatal hepatitis associated with isoniazid therapy may occur and may develop even after many months of treatment. The risk of developing hepatitis is age related.
Approximate case rates by age are: 0 per 1,000 for persons under 20 years of age, 3 per 1,000 for persons in the 20 to 34 year age group, 12 per 1,000 for persons in the 35 to 49 year age group, 23 per 1,000 for persons in the 50 to 64 year age group, and 8 per 1,000 for persons over 65
Therefore, patients given isoniazid should be carefully monitored and interviewed at monthly intervals. Serum transaminase concentration becomes elevated in about 10% to 20% of patients, usually during the first few months of therapy, but it can occur at any time. Usually enzyme levels return to normal despite continuance of drug, but in some cases progressive liver
dysfunction occurs. Patients should be instructed to report immediately any of the prodromal symptoms of hepatitis, such as fatigue, weakness, malaise, anorexia, nausea, or vomiting. If
Patients with tuberculosis should be given appropriate treatment with alternative drugs. If isoniazid must be reinstituted, it should be reinstituted only after symptoms and laboratory
abnormalities have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immediately if there is any indication of recurrent liver
DESCRIPTION
stearate, sodium lauryl sulfate, sucrose, talc, acacia, titanium dioxide, kaolin, magnesium
carbonate, colloidal silicon dioxide, dried aluminum hydroxide gel, ferric oxide, black iron
Rifampin
Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform,
soluble in ethyl acetate and methanol. Its molecular weight is 822.95 and its chemical formula is C43H58N4O12. The chemical name for rifampin is either:
3-[[(4-methyl-1-piperazinyl) imino]-methyl]-rifamycin;
or
47 异烟肼(INH,isoniazid, 雷米封rimifon) ? 抗菌...51 利福平(rifampin, RFP)高效,低毒,口服方便三...吡嗪酰胺(pyrazinamide, PZA) ? 体内过程:易吸收;...
可能与isoniazid不能渗入细菌体内 ? 分枝杆菌的细胞...(rifampin) 地中海链丝菌(Streptomyces mediterranei)...无交叉抗药性 吡嗪酰胺(pyrazinamide) ? 体内有较...
(isoniazid,INH) 利福平(rifampin,RFP) 全杀菌剂 链霉素(streptomycin,SM) 吡嗪酰胺(pyrazinamide,PZA)半杀菌剂 乙胺丁醇(ethambutol,EMB) 对氨基水杨酸钠(sodium...
(isoniazid, INH, 雷米封) 1952年开始用于临床 【...26 利福平(rifampin) 【体内过程】吸收 分布 代谢 ...35 吡嗪酰胺(pyrazinamide, PZA) 胞内杀菌药 【...
(pyrazinamide, PZA) 特点:口服吸收迅速 酸性环境中...? 其抗菌机制和抗菌谱与rifampin相同,且 与rif...? 与isoniazid、乙胺丁醇等抗结核病药物有 协同作用...
(isoniazid,INH,雷米封,Rimifon) 异烟酸的衍生物,...19 利福平(rifampin,RFP,甲哌利福霉素Rifampicin) ...易耐药 32 吡嗪酰胺 (pyrazinamide,PZA) 1.酸性...
1结核分枝杆菌耐药性形成机制 结核分枝杆菌对临床常用的抗结核一线药物包括异烟肼 (isoniazid,INH)、利福平(rifampin,RFP)、吡嗪酰胺(pyrazinamide,PZA)、链霉素(...
过程非常复杂,需要联合使用上世纪五六十年代问世的 4 种主流药物: 异胭肼 (isoniazid) 乙胺丁醇 、(ethambutol) 、 呲嗪酰胺(pyrazinamide) 和利福平(rifampin) ...
(isoniazid,INH,H) 利福平(rifampin,RFP,R) 长效利福霉素类衍生物 (利福喷丁、利福布丁) 链霉素(streptomycin,SM,S) 吡嗪酰胺(pyrazinamide,PZA,Z) 乙胺丁醇...
注射剂 异烟肼Isoniazid 口服常释剂型、注射剂 呋喃妥因Nitrofurantoin口服常释剂型 吡嗪酰胺Pyrazinamide 口服常释剂型 对氨基水杨酸钠Sodium 利福平Rifampicin 口服...
热门文档